ALK-Abelló A/S (CPH:ALKB:DC), a research-driven pharmaceutical company focused on allergy prevention, diagnosis and treatment, announced on Friday that it has appointed Søren Jelert as its new chief financial officer (CFO) and executive vice president.
In his new role, Jelert will report directly to Carsten Hellmann. He is expected to take up his new role by 2 January 2018.
Jelert succeeds Flemming Pedersen, who will be leaving the company.
Most recently, since 2016, Jelert has been general manager of NNE's US organisation. Prior to that, from 2008 until 2016, he was CFO at NNE. Before that, his experience includes various finance roles at Novo Nordisk and Maersk.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary